Recce Pharmaceuticals Ltd

RCE

AU000000RCE5

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:59:46 2024-06-03 am EDT			5-day change	1st Jan Change
0.58 ^AUD	-0.85%		+1.75%	+8.41%

May. 17	Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	CI
May. 15	Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	MT

Recce Limited Announces the Resignation of Dominic Barnes as Director

January 22, 2017 at 04:25 pm EST

Dominic Barnes has notified the Recce Limited of his resignation as a director with immediate effect.

Latest news about Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	May. 17	CI
Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	May. 15	MT
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study	May. 13	CI
Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	May. 10	MT
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	May. 08	CI
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives	May. 07	MT
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	Apr. 30	CI
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	Apr. 17	CI
Recce Pharmaceuticals Advances Production of Anti-Infective Medication	Apr. 16	MT
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives	Apr. 04	CI
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%	Apr. 02	MT
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications	Mar. 20	MT
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis	Mar. 19	CI
Recce Pharmaceuticals Concludes Cohort Dosing in Synthetic Anti-Infectives Trial	Mar. 14	MT
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis	Mar. 14	CI
Recce Makes Headway On Human Trials of Anti-Infective	Mar. 13	MT
Recce Pharmaceuticals Secures AU$11.2 Million R&D Advance; Shares Up 5%	Mar. 07	MT
Recce Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Recce Pharmaceuticals Establishes Strategic Partnership with Pt Etana Biotechnologies in South-East Asia to Accelerate Clinical Program	Feb. 07	CI
Recce Pharmaceuticals Enters Deal with Etana Biotechnologies for Anti-Infective Portfolio Development; Shares Climb 7%	Feb. 05	MT
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections	Jan. 23	CI
Recce Pharmaceuticals Receives Positive Efficacy Data in UTI Animal Study	Dec. 27	MT
Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program	Dec. 19	CI
Recce Pharmaceuticals Publishes Positive Result of Independent Study on Recce 327	Dec. 15	MT
Recce Pharmaceuticals Secures AU$47.8 Million Advanced Overseas Finding Award from AusIndustry	Dec. 14	MT

Chart Recce Pharmaceuticals Ltd

Duration

Period

More charts

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Companyâs anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Companyâs anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are 100% water soluble at all pH levels in their liquid form.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Recce Pharmaceuticals Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RECCE PHARMACEUTICALS LTD	+8.41%	79.23M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.50%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+9.53%	210B
ROCHE HOLDING AG	-5.36%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals

Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Pharmaceuticals

Recce Limited Announces the Resignation of Dominic Barnes as Director

Latest news about Recce Pharmaceuticals Ltd

Chart Recce Pharmaceuticals Ltd

Company Profile

Income Statement Evolution

Ratings for Recce Pharmaceuticals Ltd

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals